- In accordance with Israeli regulations, demand letter has been sent to MDGS and meeting of company shareholders must be held within 21 days of letter’s date
- Pure Capital Ltd. says that it is committed to raising MDGS shareholder value through the process of replacing internal members of the board of directors
- Replacement nominees are led by Professor Benad Goldwasser, a urological surgeon, inventor and entrepreneur; all nominees have been vetted, according to Pure Capital
Privately-held investment firm Pure Capital Ltd. yesterday announced that it has acquired 217,696 ADRs of Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), bringing its total ownership stake to greater than five percent of the Israeli medical device company (http://nnw.fm/Al6uN). In accordance with Israeli regulations, Pure Capital has sent a letter to Medigus’ CEO, board chairman and board of directors seeking an immediate general assembly meeting of the MDGS shareholders and the dismissal of its internal members of the board.
In the letter, Pure Capital details a number of recent corporate actions that it believes have been harmful to the company’s shareholders. They include continual capital consolidations and capital raises under unfavorable terms. Further, Pure Capital has asked MDGS to avoid raising capital, making public or private offerings and executing disposition of assets until the meeting has taken place.
In a news release issued earlier this week, Pure Capital noted that it is committed to substantially increasing MDGS’s shareholder value and fully replacing the members of its board. According to Israeli regulations, the requested meeting must be held no later than 21 days from the date of the letter of demand.
A team of replacement nominees, as detailed by Pure Capital, is led by Professor Benad Goldwasser. He is a urological surgeon and co-founder of Medinol Ltd., an Israeli medical device company. He and the other nominees have been carefully vetted and were selected after a thorough due diligence process by Pure Capital.
Pure Capital has led various transactions and capital raises totaling over $200 million over the past two years in the U.S., Canada and Israel.
MDGS is a medical device company specializing in developing innovative imaging solutions and minimally invasive endosurgical tools. The company also developed the MUSE™ system endoscopic device, which is designed for the treatment of gastroesophageal reflux disease (GERD).
For more information, visit the company’s website at www.Medigus.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment